SMAD2 and renal fibrosis: A study showed that in paclitaxel-treated renal fibrosis animal models, inhibition of TGF-β/SMAD-2/3 signaling and mitigation of renal fibrosis, which were accompanied by downregulation of miR-192, probably implied the regulatory relationship between miR-192 and the canonical TGF-β signaling pathway (Sun et al., 2011).